Physician profile
Michael P Potts
NPI 1184619074
$2,389.83
in general payments reported to CMS, 2019-2025
23 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $210 · 2021: $241 · 2022: $676 · 2023: $460 · 2024: $88.43 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $372.98 | 2020-2025 | Jot Dx |
| Astellas Pharma US INC | $313.95 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $231.48 | 2019-2022 | |
| Medtronic Vascular, INC. | $228.41 | 2019-2020 | |
| Pfizer INC. | $174.49 | 2022-2025 | |
| Medtronic, INC. | $161.35 | 2023 | Linq II |
| Amgen INC. | $150.48 | 2020-2023 | Repatha |
| Merck Sharp & Dohme LLC | $149.06 | 2023-2025 | Verquvo |
| Amarin Pharma, INC. | $130.00 | 2019 | |
| Atricure, INC. | $94.43 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System, Synergy Ablation System |
| Irhythm Technologies, INC. | $83.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.38 | 2019-2024 | |
| Impulse Dynamics (USA) INC. | $40.93 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.02 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $31.08 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $26.50 | 2025 | Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $24.46 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $19.74 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.23 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.09 | 2025 | Wainua |
| Edwards Lifesciences Corporation | $14.88 | 2019 | |
| Ge Healthcare | $13.60 | 2019 | |
| Cvrx, INC. | $11.49 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Potts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.